Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Rexulti Misses Mark in PII BPD Trial: Otsuka
August 19, 2021
- Yamasa Ramps Up API CMO Biz for Oligonucleotides, mRNA Drugs amid Changes in Modalities
August 19, 2021
- Wakamoto Grants North American Rights for MaQaid to Harrow
August 19, 2021
- Otsuka Wins Japan Approval for OD Tablet Form of Rexulti
August 19, 2021
- 1st Drug for Short Bowel Syndrome Now Available in Japan: Takeda
August 19, 2021
- Sawai to Suspend Shipments of Loperamide Capsules after Foreign Matter Identified
August 19, 2021
- Nichi-Iko, Medipal Form Capital Tie-Up; 5.2 Billion Yen Investment Goes towards CapEx
August 18, 2021
- MSD to Lift Shipment Restrictions on Pneumovax
August 18, 2021
- AnGes Launches PI/II Study for High-Dose COVID-19 Vaccine
August 18, 2021
- Choseido Likely to Face Administrative Penalty over Manufacturing Flaws
August 18, 2021
- 1st Patient Dosed in Multinational PII Study of Brincidofovir: SymBio
August 18, 2021
- AbbVie to Begin Clinical Development of Schizophrenia Drug in Japan
August 18, 2021
- Japan Pharma Market Delivers 1st Growth in 5 Qtrs in April-June: IQVIA
August 18, 2021
- Teva Takeda Set to Roll Out 2nd Blopress AG but Denies Competition with ASKA
August 17, 2021
- Eisai Rolls Out Tazverik for EZH2-Positive Follicular Lymphoma
August 17, 2021
- OBP-601 to Enter US PII for Neurodegenerative Diseases: Oncolys
August 17, 2021
- Boehringer Joins NCC’s Rare Cancer Project
August 16, 2021
- Sandoz Curbs Shipments of Leprosy Drug, Hints at Supply Halt
August 16, 2021
- Probe Panel Urges Ono to Establish Foundation to Handle Scholarship Donations after Bribery Case
August 16, 2021
- Ono, MiraBiologics Ink Biologics Discovery Deal
August 16, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…